Brian G. Feagan
University of Western Ontario
Internal medicineSurgeryRandomized controlled trialIntensive care medicinePhysical therapyAdverse effectImmunologyPlaceboVedolizumabInfliximabInflammatory bowel diseaseMaintenance therapyUstekinumabDiseaseCrohn's diseaseUlcerative colitisIn patientClinical trialMedicineGastroenterology
930Publications
115H-index
48.9kCitations
Publications 847
Newest
#1Jurij Hanzel (Ljubljana University Medical Centre)H-Index: 5
#2Christopher MaH-Index: 21
Last. Brian G. FeaganH-Index: 115
view all 6 authors...
Source
#1Eileen Crowley (London Health Sciences Centre)H-Index: 6
#2Christopher Ma (U of C: University of Calgary)H-Index: 21
Last. Vipul Jairath (UWO: University of Western Ontario)H-Index: 20
view all 6 authors...
BACKGROUND AND AIMS Timely access to approved medications is a priority in paediatric inflammatory bowel disease (IBD). To date, the timing of drug studies in paediatric IBD has been suboptimal with most studies conducted long after approval has been granted for adult IBD. This delay in approval leads to extensive off-label prescribing of medications in children, often without clear guidance on optimal dosing. The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have i...
Source
#1Hyuk Yoon (UCSD: University of California, San Diego)H-Index: 2
#1Hyuk Yoon (UCSD: University of California, San Diego)H-Index: 2
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 67
view all 8 authors...
Background Although achieving histologic remission in ulcerative colitis is established, the incremental benefit of achieving histologic remission in patients with Crohn disease (CD) treated to a target of endoscopic remission is unclear. We evaluated the risk of treatment failure in patients with CD in clinical and endoscopic remission by histologic activity status. Methods In a single-center retrospective cohort study, we identified adults with active CD who achieved clinical and endoscopic re...
1 CitationsSource
#1Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 32
#2Brian G. FeaganH-Index: 115
Last. William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
view all 8 authors...
Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody concentrations in individuals to guide treatment decisions. In patients with Crohn disease (CD), TDM, used either reactively or proactively, is emerging as a valuable tool for optimization of tumor necrosis factor (TNF) antagonist therapy. Reactive TDM is carried out in response to treatment failure, whereas proactive TDM involves the periodic monitoring of patients responding to TNF antagonist therapy to allow tr...
3 CitationsSource
#1Rocio Sedano (UWO: University of Western Ontario)H-Index: 3
Last. Robert Battat (Cornell University)H-Index: 18
view all 17 authors...
BACKGROUND AND AIMS Quantifying placebo rates and the factors influencing them are essential to inform trial design. We provided a contemporary summary of clinical, endoscopic, histologic and safety placebo rates in induction and maintenance clinical trials of ulcerative colitis, and identify factors influencing them. METHODS MEDLINE, EMBASE, and the Cochrane library were searched from April-2014 to April-2020, updating a prior meta-analysis that searched from inception to April-2014. We include...
Source
#2Christopher Ma (U of C: University of Calgary)H-Index: 21
#3Alain M. Schoepfer (CHUV: University Hospital of Lausanne)H-Index: 59
Last. Sandeep K. Gupta (IU: Indiana University)H-Index: 36
view all 72 authors...
ABSTRACT null Background null Endpoints used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments. null Objective null To develop a core outcome set (COS) for controlled and observational studies of pharmacologic and diet interventions in adult and pediatric patients with EoE. null Method...
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
view all 12 authors...
BACKGROUND AND AIMS This analysis examined long-term safety and efficacy of ozanimod in patients with moderate-to-severe UC with ≥4 years of follow-up in the phase 2 TOUCHSTONE open-label extension (OLE). METHODS Patients receiving placebo or ozanimod HCl 0.5 mg or 1 mg during the double-blind period could enter the OLE (ozanimod HCl 1 mg daily). Partial Mayo score (pMS) clinical response and remission were assessed through OLE week 200 and summarized descriptively using observed cases (OC) and ...
2 CitationsSource
#1Rocio Sedano (UWO: University of Western Ontario)H-Index: 3
#2Tran M NguyenH-Index: 16
Last. Christopher Ma (U of C: University of Calgary)H-Index: 21
view all 11 authors...
Background null Several indices exist to measure pouchitis disease activity; however, none are fully validated. As an initial step toward creating a validated instrument, we identified pouchitis disease activity indices, examined their operating properties, and assessed their value as outcome measures in clinical trials. null Methods null Electronic databases were searched to identify randomized controlled trials including indices that evaluated clinical, endoscopic, or histologic pouchitis dise...
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Subrata Ghosh (University of Birmingham)H-Index: 85
view all 13 authors...
Background Ustekinumab is currently approved globally in Crohn's disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn's disease and UC phase 3 programs had similar study designs, facilitating integrated safety analyses. Methods Data from 6 ustekinumab phase 2/3 CD and UC studies were pooled, and safety was evaluated through 1 year. Patients received 1 placebo or ustekinumab (generally 130 mg or ~6 mg/kg) intravenous induction, the...
12 CitationsSource
#1Marc Ferrante (Katholieke Universiteit Leuven)H-Index: 59
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
view all 15 authors...
BACKGROUND AND AIMS Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity, and efficacy of risankizumab in responders to risankizumab in the parent phase 2 study. METHODS Enrolled patients had achieved clinical response (decrease in Crohn's Disease Activity Index from baseline ≥100) without...
Source